We're Not Worried About LTR Pharma's (ASX:LTP) Cash Burn
Oct 18
Have your own idea? Try our Stock Screener
Australian (ASX) Pharma Industry Analysis
UpdatedJan 16, 2026
DataAggregated Company Financials
Companies26
- 7D-3.2%
- 3M-12.2%
- 1Y2.3%
- YTDn/a
Over the last 7 days, the Pharma industry has dropped 3.2%, driven by a pullback from Clarity Pharmaceuticals of 14%. In contrast, Neuren Pharmaceuticals has gained 5.1%. As for the longer term, the industry's performance has been flat for the past year. Earnings are forecast to grow by 33% annually.
Industry Valuation and Performance
Has the Australian Pharma Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Fri, 16 Jan 2026 | AU$5.6b | AU$1.0b | -AU$199,680,775.00 | 16.5x | -28.2x | 5.6x |
| Sun, 14 Dec 2025 | AU$5.4b | AU$1.0b | -AU$199,680,775.00 | 14.4x | -26.9x | 5.4x |
| Tue, 11 Nov 2025 | AU$6.0b | AU$1.0b | -AU$202,211,775.00 | 14.1x | -29.5x | 6x |
| Thu, 09 Oct 2025 | AU$6.6b | AU$1.0b | -AU$202,211,775.00 | 14.3x | -32.7x | 6.6x |
| Sat, 06 Sep 2025 | AU$5.5b | AU$1.0b | -AU$202,211,775.00 | 14.5x | -27x | 5.5x |
| Mon, 04 Aug 2025 | AU$5.6b | AU$1.0b | -AU$210,394,927.00 | 15x | -26.6x | 5.5x |
| Wed, 02 Jul 2025 | AU$4.6b | AU$1.1b | -AU$225,511,927.00 | 14.9x | -20.2x | 4.3x |
| Fri, 30 May 2025 | AU$4.6b | AU$1.0b | -AU$238,266,485.00 | 17.6x | -19.4x | 4.4x |
| Sun, 27 Apr 2025 | AU$4.4b | AU$1.0b | -AU$238,266,485.00 | 17.3x | -18.6x | 4.3x |
| Tue, 25 Mar 2025 | AU$4.9b | AU$1.1b | -AU$289,508,485.00 | 19.1x | -16.9x | 4.6x |
| Thu, 20 Feb 2025 | AU$5.4b | AU$1.0b | -AU$382,679,059.00 | 14.2x | -14.1x | 5.3x |
| Sat, 18 Jan 2025 | AU$5.3b | AU$1.0b | -AU$378,981,112.00 | 12.5x | -14.1x | 5.3x |
| Mon, 16 Dec 2024 | AU$5.4b | AU$1.0b | -AU$378,981,112.00 | 12.1x | -14.3x | 5.3x |
| Wed, 13 Nov 2024 | AU$7.0b | AU$1.0b | -AU$377,703,112.00 | 14.3x | -18.5x | 6.9x |
| Fri, 11 Oct 2024 | AU$6.4b | AU$1.0b | -AU$377,703,112.00 | 14x | -17x | 6.3x |
| Sun, 08 Sep 2024 | AU$6.5b | AU$1.0b | -AU$383,620,117.00 | 13.9x | -16.9x | 6.4x |
| Tue, 06 Aug 2024 | AU$5.9b | AU$995.3m | -AU$387,920,108.00 | 10.7x | -15.1x | 5.9x |
| Thu, 04 Jul 2024 | AU$6.3b | AU$995.3m | -AU$387,920,108.00 | 11.5x | -16.3x | 6.3x |
| Sat, 01 Jun 2024 | AU$6.6b | AU$1.2b | -AU$344,938,684.00 | 13.8x | -19.1x | 5.5x |
| Mon, 29 Apr 2024 | AU$5.4b | AU$1.2b | -AU$374,923,684.00 | 13.8x | -14.4x | 4.5x |
| Wed, 27 Mar 2024 | AU$5.6b | AU$1.2b | -AU$374,923,684.00 | 14.9x | -15x | 4.6x |
| Fri, 23 Feb 2024 | AU$5.3b | AU$897.1m | -AU$529,973,278.00 | 20.8x | -10.1x | 6x |
| Sun, 21 Jan 2024 | AU$5.7b | AU$896.3m | -AU$589,604,392.00 | 20.8x | -9.6x | 6.3x |
| Tue, 19 Dec 2023 | AU$5.3b | AU$896.3m | -AU$589,604,392.00 | 18.5x | -8.9x | 5.9x |
| Thu, 16 Nov 2023 | AU$4.1b | AU$893.0m | -AU$595,020,018.00 | 19x | -6.8x | 4.6x |
| Sat, 14 Oct 2023 | AU$3.5b | AU$900.3m | -AU$587,952,018.00 | 19.8x | -5.9x | 3.9x |
| Mon, 11 Sep 2023 | AU$3.7b | AU$900.3m | -AU$587,952,018.00 | 19.3x | -6.2x | 4.1x |
| Wed, 09 Aug 2023 | AU$4.0b | AU$999.0m | -AU$624,794,303.00 | 21.2x | -6.4x | 4x |
| Fri, 07 Jul 2023 | AU$4.1b | AU$999.0m | -AU$624,794,303.00 | 24.9x | -6.5x | 4.1x |
| Sun, 04 Jun 2023 | AU$4.1b | AU$999.0m | -AU$624,794,303.00 | 20.4x | -6.5x | 4.1x |
| Tue, 02 May 2023 | AU$4.2b | AU$993.2m | -AU$641,969,868.00 | 20.9x | -6.6x | 4.2x |
| Thu, 30 Mar 2023 | AU$4.1b | AU$995.9m | -AU$648,651,745.00 | 17x | -6.2x | 4.1x |
| Sat, 25 Feb 2023 | AU$3.6b | AU$992.6m | -AU$594,888,272.00 | 17.9x | -6x | 3.6x |
| Mon, 23 Jan 2023 | AU$4.1b | AU$951.8m | -AU$584,038,383.00 | 17.2x | -6.9x | 4.3x |
Price to Earnings Ratio
-6.9x
Current Industry PE
- Investors are optimistic on the Australian Pharmaceuticals industry, and appear confident in long term growth rates.
- The 3-year average PS ratio of 5.1x is lower than the industry's current PS ratio of 5.6x.
Past Earnings Growth
- The earnings for companies in the Pharmaceuticals industry have improved over the last three years.
- Meanwhile revenues have remained mostly flat.
- This means that companies overall are more efficiently conducting business since losses are shrinking while sales have been flat.
Industry Comparison
How does Australian Pharma compare with similar industries?
| AU Market | 1.60% | |
| Healthcare | -0.18% | |
| Pharma | -3.24% | |
| Pharma | -3.24% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| NEU Neuren Pharmaceuticals | AU$19.71 | 5.1% +AU$120.3m | 60.5% | PE16.7x | |
| VLS Vita Life Sciences | AU$2.82 | 7.6% +AU$10.9m | 41.7% | PE16.5x | |
| RCE Recce Pharmaceuticals | AU$0.70 | 5.2% +AU$10.1m | 46.9% | PS27.2x | |
| BOT Botanix Pharmaceuticals | AU$0.14 | 3.7% +AU$9.8m | -70.2% | PS47.6x | |
| SNT Syntara | AU$0.035 | 6.1% +AU$3.3m | -53.3% | PS7.8x |